SCHOTT Pharma dividend and valuation

1SXP · Xetra · EUR

Compare SCHOTT Pharma
€22.45Change from previous close: +0.22%Absolute change: +€0.05

Close · November 17, 2026

Valuation

SCHOTT Pharma paid €0.18 per share in dividends over the last 12 months (yield 0.8%). Last ex-dividend date: February 4, 2026. The P/E ratio is 24.8. The average price target of 13 analysts is €25.03.

Data as of November 16, 2026

SCHOTT Pharma compared with similar companies

SCHOTT Pharma's P/E (trailing 12 months): 24.8, in line with the median of a group of 9 similar companies (25.2).

SCHOTT Pharma's metrics compared with similar companies
MetricSCHOTT PharmaMedian25th–75th percentileBand
P/E (trailing 12 months)24.825.219.9 – 34.4Middle
Forward P/E20.420.415.6 – 30.0Middle
EV/EBITDA13.513.510.1 – 17.7Middle
Price/book3.343.342.20 – 5.20Middle
Price/sales3.301.981.43 – 3.41Middle
Gross margin31.2%51.6%36.4% – 59.1%Low
Operating margin16.4%13.7%7.2% – 17.6%Middle
Net margin13.4%6.0%5.2% – 11.0%High
ROE14.7%11.5%6.1% – 24.9%Middle
Debt/equity0.310.350.23 – 1.04Middle

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Other metrics

Valuation multiples

Market cap
€3.36B
Enterprise value
€3.64B
PEG
2.09
EV/revenue
3.58

Profitability and growth

ROA
6.5%
ROIC
8.5%
Revenue growth (year over year)
10.0%
Earnings growth (year over year)
-13.3%

Financial health

Total cash
€24.88M
Total debt
€308.26M
Current ratio
1.61
Quick ratio
0.74
Altman Z-Score
3.78
Piotroski F-Score
5.00

Dividends

Annual dividend per share
€0.18
Dividend yield
0.8%
Payout ratio
20.0%
Ex-dividend date
February 4, 2026

Analysts and estimates

Average price target
€25.03
Median price target
€25.00
High price target
€29.20
Low price target
€17.30
Analysts with a price target
13
Consensus
Buy
Forward EPS
€1.09
EPS estimate, current year
€0.99

Shares and trading

Beta
0.86
Average volume
78.05K
Shares outstanding
150.61M
Float
34.35M
Institutional ownership
20.2%
Insider ownership
77.0%